Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan.
In 7 of 8 children with idiopathic pulmonary arterial hypertension treated with intravenous epoprostenol for >1 year, concomitant use of bosentan allowed a reduction of epoprostenol and decreased its associated side effects without deterioration of clinical and hemodynamic parameters. In 3 children with normal or near-normal pulmonary artery pressure on epoprostenol, the addition of bosentan allowed discontinuation of epoprostenol and stabilization of hemodynamics for up to 1 year.
Ivy
D Dunbar
DD
Pediatric Cardiology, Pediatric Pulmonary Hypertension Program, Pediatric Heart Lung Center, Department of Pediatrics, The Children's Hospital, University of Colorado, Denver 80218, USA. ivy.dunbar@tchden.org
Doran
Aimee
A
Claussen
Lori
L
Bingaman
Deborah
D
Yetman
Anji
A
D000293:Adolescent; D000959:Antihypertensive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001794:Blood Pressure / Q000502:physiology; D000077300:Bosentan; D002648:Child; D002675:Child, Preschool; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D011464:Epoprostenol / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000503:physiopathology*; D008297:Male; D013449:Sulfonamides / Q000008:administration & dosage*; D014655:Vascular Resistance / Q000502:physiology
D000959:Antihypertensive Agents; D013449:Sulfonamides; D011464:Epoprostenol; D000077300:Bosentan